Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Understanding Leukaemia and Related Cancers

May 1, 2000
By Tariq I. Mughal, MB, MD, MRCP, FACP
Mary Cianfrocca, DO
Publication
Article
OncologyONCOLOGY Vol 14 No 5
Volume 14
Issue 5

Patients who have newly diagnosed leukemia are often overwhelmed with the complexities of their disease and its required therapy. In their book, Understanding Leukaemia and Related Cancers, Drs. Mughal and Goldman offer patients a

 Patients who have newly diagnosed leukemia are often overwhelmed with the complexities of their disease and its required therapy. In their book, Understanding Leukaemia and Related Cancers, Drs. Mughal and Goldman offer patients a valuable guide to the diagnosis and treatment of leukemia. The authors note that the book is intended for a varied audience, but I believe that it will be most useful to patients and family members who seek a better understanding of the disease and its implications.

The book consists of eight chapters, the first three of which attempt to provide readers with the scientific background that will help them gain a better understanding of the disease process. The authors have done an excellent job of explaining complicated medical information in relatively easy-to-understand language, and the well-chosen illustrations will likely add to the reader’s comprehension.

The prevalence of leukemia, as well as the possible etiologies for its development, are discussed. Many patients fear that they may have done something to cause their cancer, and the authors go to some length to try to dispel these concerns. They also provide a valuable resource in Appendix 1—a list of many active support organizations in the United Kingdom, the United States, and Spain.

The remaining chapters describe the diagnosis and treatment of the various types of leukemia. Clear, simple language is used to explain the usual work-up that is performed on the leukemia patient, as well as the rationale behind various procedures.

The potential benefits and toxicities of chemotherapy and radiation are discussed, and a separate chapter on bone marrow transplantation is also included. The authors remember to include toxicities that occur with certain therapies, such as red urine with daunorubicin (Cerubidine), that are not dangerous but that, nonetheless, may be frightening to the unprepared patient.

The authors also address the importance of patient participation in clinical trials. They make the important point that 90% of children in the United Kingdom with acute lymphoblastic leukemia—a disease in which tremendous advances have been made—are entered into clinical trials.

Although the chapter on leukemia therapy is well written, it contains a few inaccuracies. For example, the section on the treatment of hairy-cell leukemia is outdated: Treatment with interferon is emphasized, and 2-chlorodeoxyadenosine (cladribine [Leustatin]) is mentioned only briefly. Also, the authors state that high-dose cytarabine is used only occasionally when, in fact, it has now become the standard consolidation therapy for many patients with acute myeloid leukemia.

The book’s final chapter ends on a hopeful note by discussing future therapeutic prospects. Targeted therapy, such as gene therapy, is described, as well as some of the controversies surrounding bone marrow transplantation.

Any book that informs patients is always a valuable resource. Despite its few shortcomings, Understanding Leukaemia and Related Cancers provides patients and their families with much of the information that they will need for proper decision-making throughout the course of their disease. It also manages to present this complicated information in a simple, nonthreatening manner. Patients will likely find this book to be most useful as a starting point for further discussion with their physicians.

Articles in this issue

Medicare Rethinking Its Policy on Self-Injectables
Home Counseling Program for Women With Lung Cancer to Be Studied
New Indication Sought for Bicalutamide
Approval of Antibody-Targeted Chemotherapy Recommended
NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer Planned
First Comparison of Anastrozole vs Tamoxifen
Prolonged Androgen Blockade May Boost Survival in Advanced Prostate Cancer
FDA Approves Irinotecan as First-Line Therapy for Colorectal Cancer
Understanding Leukaemia and Related Cancers
Bill Will Allow Doctors to Negotiate Jointly With HMOs
New Drug for Refractory Cutaneous T-Cell Lymphoma
New Clinical Trials Data Bank
Exisulind Shows Positive Results in the Prevention of Precancerous Colon Polyps
Commentary (Hewitt): An Alternative Algorithm for Dosing Transdermal Fentanyl for Cancer-Related Pain
Commentary (Carr/Goudas): An Alternative Algorithm for Dosing Transdermal Fentanyl for Cancer-Related Pain

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC

Roman Fabbricatore
July 15th 2025
Article

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape

Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape

Ariana Pelosci
July 15th 2025
Article

Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

Tarbia Hamid;Laura Manfroi;Hiral Thakkar;Samir Mitri
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Kristi Rosa
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Related Content

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC

Roman Fabbricatore
July 15th 2025
Article

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape

Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape

Ariana Pelosci
July 15th 2025
Article

Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

Tarbia Hamid;Laura Manfroi;Hiral Thakkar;Samir Mitri
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Kristi Rosa
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.